Tempus AI (NASDAQ:TEM) Raised to Hold at Freedom Capital

Tempus AI (NASDAQ:TEM) was upgraded by Freedom Capital to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Wolfe Research began coverage on Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research report on Monday, June 1st. HC Wainwright lowered their target price on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Finally, Morgan Stanley decreased their price target on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $68.54.

Tempus AI Stock Performance

NASDAQ TEM opened at $61.60 on Tuesday. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. Tempus AI has a 12-month low of $41.73 and a 12-month high of $104.32. The firm has a 50-day moving average price of $50.28 and a two-hundred day moving average price of $54.60. The company has a market capitalization of $11.06 billion, a P/E ratio of -35.81 and a beta of 3.45.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same quarter last year, the company earned ($0.24) EPS. The company’s revenue was up 36.1% on a year-over-year basis. Analysts anticipate that Tempus AI will post -1.35 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Ryan Fukushima sold 13,550 shares of Tempus AI stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $597,148.50. Following the completion of the transaction, the chief executive officer owned 603,558 shares in the company, valued at $26,598,801.06. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $57.48, for a total transaction of $9,556,050.00. Following the completion of the transaction, the chief executive officer owned 8,775,283 shares of the company’s stock, valued at $504,403,266.84. This represents a 1.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 572,759 shares of company stock worth $29,238,424 in the last ninety days. 24.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently added to or reduced their stakes in the business. JPL Wealth Management LLC bought a new position in shares of Tempus AI in the 3rd quarter worth $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Tempus AI during the third quarter valued at approximately $38,000. Whittier Trust Co. grew its holdings in Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after acquiring an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC bought a new position in shares of Tempus AI during the fourth quarter valued at approximately $42,000. 24.22% of the stock is currently owned by institutional investors.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Analyst-style coverage argued Tempus AI remains attractive because of diagnostics momentum, AI platform expansion, and recent FDA-related product gains that may broaden future growth. Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
• Positive Sentiment: Some market commentary suggested the recent pullback may be creating a buying opportunity for investors who believe in Tempus AI’s long-term growth story. Tempus AI stock faces a make-or-break moment after its recent pullback
• Neutral Sentiment: Konica Minolta completed the sale of Tempus shares it previously received, which may remove a supply overhang but is not an operating update. Konica Minolta Completes Sale of Tempus Shares to Bolster Balance Sheet
• Negative Sentiment: Biovica said it is refocusing its U.S. commercial strategy and terminating its agreement with Tempus AI, which could reduce a partnership-related opportunity. Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
• Negative Sentiment: Recent insider selling by the CFO, CEO, and a director may be pressuring sentiment, even though the trades were made under pre-arranged plans. Tempus AI CEO insider sale filing

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.